Schering-Plough and Upjohn Enjoy Gains

Schering-Plough and Upjohn, two leading health-care concerns, said profits climbed steeply in the third quarter over last year due to strong worldwide pharmaceutical sales.

Schering-Plough reported that net income jumped 42.2% to $62.3 million from $43.8 million in last year’s third quarter.

The Madison, N.J.-based maker of health-care products and consumer items said revenue amounted to $600.6 million, an 18.5% increase over the $506.7 million rung up in last year’s quarter.

Upjohn, headquartered in Kalamazoo, Mich., said third-quarter net income rose 29.2% to $60.6 million from $46.9 million in the year-ago period. Revenue totaled $561.2 million, 18.2% higher than the $474.7 million in the quarter ended Sept. 30, 1985.

Sales were led by two drugs to treat nervous-system disorders, Xanax and Halcion, and by Micronase, a drug taken orally to treat diabetes.